Stribild Lawsuit

Gilead Sciences has reaped huge profits from sales of its HIV drug, tenofovir disoproxyl fumurate (“TDF”). In various combinations with other medications, Gilead markets TDF under several brand names, including Stribild. Recently-filed lawsuits suggest that Gilead sought to improperly extend its profits by suppressing the approval process of a safer alternative (“TAF”).

HIV Litigation Attorneys™ represents plaintiffs in Stribild lawsuits who claim to have suffered serious bone injuries and kidney damage as a result of their long-term use of the TDF-based HIV medication.

Stribild Allegations, Injuries, and the Statute of Limitations

The plaintiffs in the Stribild lawsuits allege that Gilead breached its duty to effectively warn patients about the potential for serious bone loss and kidney damage that may occur with regular use of TDF medication. They also allege that Gilead failed to minimize those risks when it withheld from the marketplace the development of a safer pharmaceutical.

The plaintiffs are seeking damages on account of the bone and kidney problems that they have suffered after they were prescribed a TDF drug regimen. Thousands of other HIV patients are potentially suffering similar injuries and, to the extent that Gilead ‘s conduct is found to have been the cause of those injuries, they may be eligible to receive compensation for their damages as well.

Applicable statutes of limitations will be a critical consideration in initiating a claim for that compensation. Injured parties generally have between two and three years after they become aware of their injuries or illnesses and their potential causes to file a lawsuit. Many current HIV patients began using TDF in the mid-2000’s. To avoid statute of limitations problems, any patient who has been using TDF and has received a diagnosis of bone or kidney problems should not hesitate to contact legal counsel for further investigation.  

Stribild Lawsuits Suggest Gilead Delayed Safer Alternative to TDF

Because of how exclusivity periods apply to drug products, Gilead has maintained its position as the exclusive producer of TDF for an extended period of time while it derived significant profits from that drug. It will now have an additional extended period in which it will be the exclusive producer of TAF.

Gilead thus appears to have structured its drug development and research program to maximize its profits rather then to introduce safer forms of a drug into the marketplace. This conduct has potentially led to the bone and kidney problems alleged in Stribild lawsuits.

HIV Litigation Attorneys™ : Now Investigating  Claims by Stribild Users

Courtney Conner, Liza Brereton, and Arti Bhimani of HIV Litigation Attorneys™ are leading the charge against Gilead.

If you have taken Stribild (or any other TDF drug) for the treatment or prevention of HIV and have experienced symptoms of bone or kidney problems, the statute of limitations may already be running with respect to your claim. Please call to schedule a free evaluation of your potential lawsuit. You will incur no costs or expenses unless we accept your case and are able to recover damages on your behalf. We look forward to hearing from you.

Additional Resources:

  1. www.latimes.com: Patients Sue Gilead, Saying Drug Company Intentionally Deferred Safer HIV Medicine.  https://www.latimes.com/business/la-fi-gilead-hiv-drug-lawsuit-20180509-story.html
  2. www.natlawreview.com: Gilead Facing Multiple Claims of Purposefully Delaying Safer HIV Drug Alternatives. https://www.natlawreview.com/article/gilead-facing-multiple-claims-purposefully-delaying-safer-hiv-drug-alternatives
  3. www.poz.com: New Lawsuits Against Gilead Over Its HIV Med Tenofovir. https://www.poz.com/article/new-lawsuits-gilead-hiv-med-tenofovir
  4. www.aidshealth.org: Lujano et al. v. Gilead Science, Inc. https://www.aidshealth.org/wp-content/uploads/2018/05/gilead-personal-injury-final.pdf
  5. www.aidshealth.org: Martinez et al. v. Gilead Sciences, Inc. https://www.aidshealth.org/wp-content/uploads/2018/05/class-action-complaint-final.pdf